Format

Send to

Choose Destination
Arch Dermatol. 2010 May;146(5):478-82. doi: 10.1001/archdermatol.2010.59.

High-dose treatment with vitamin A analogues and risk of fractures.

Author information

1
The Osteoporosis Clinic, Aarhus Amtssygehus, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark. p-vest@post4.tele.dk

Abstract

OBJECTIVE:

To study fracture risk associated with use of systemic vitamin A analogue (isotretinoin and acitretin) treatment.

DESIGN:

Case-control study.

SETTING:

Nationwide registry.

PARTICIPANTS:

A total of 124 655 patients with fractures (cases) and 373 962 age- and sex-matched controls. Main Outcome Measure Incidence of fractures in patients with and without exposure to systemic vitamin A analogues. Confounder control was performed for social variables, contacts with hospitals and general practitioners, alcoholism, and a number of other variables known to potentially affect fracture risk, including use of systemic, intramuscular, and topical corticosteroids and antiepileptic drugs and comorbid conditions.

RESULTS:

No trend in risk of any fracture or of hip, forearm, or spine fractures was present with increasing doses or durations of treatment with vitamin A analogues. Subdividing vitamin A analogues into isotretinoin and acitretin did not change the results.

CONCLUSION:

Risk of fracture is not associated with vitamin A analogue treatment.

PMID:
20479294
DOI:
10.1001/archdermatol.2010.59
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center